CA2164410C - Emulsions as contrast agents and method of use - Google Patents
Emulsions as contrast agents and method of use Download PDFInfo
- Publication number
- CA2164410C CA2164410C CA002164410A CA2164410A CA2164410C CA 2164410 C CA2164410 C CA 2164410C CA 002164410 A CA002164410 A CA 002164410A CA 2164410 A CA2164410 A CA 2164410A CA 2164410 C CA2164410 C CA 2164410C
- Authority
- CA
- Canada
- Prior art keywords
- emulsion
- gas
- stabilizer
- ultrasonic
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims description 5
- 239000002872 contrast media Substances 0.000 title description 4
- 239000000126 substance Substances 0.000 claims abstract description 50
- 239000003381 stabilizer Substances 0.000 claims abstract description 29
- 239000012216 imaging agent Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000011159 matrix material Substances 0.000 claims description 15
- 230000002209 hydrophobic effect Effects 0.000 claims description 13
- 108010088751 Albumins Proteins 0.000 claims description 11
- 102000009027 Albumins Human genes 0.000 claims description 11
- 239000003981 vehicle Substances 0.000 claims description 11
- 229960004692 perflenapent Drugs 0.000 claims description 10
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims description 10
- 238000012285 ultrasound imaging Methods 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 6
- 229920005615 natural polymer Polymers 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 229920001059 synthetic polymer Polymers 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 6
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- 239000007789 gas Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000009835 boiling Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 229920001983 poloxamer Polymers 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 6
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 6
- 229940117972 triolein Drugs 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101150041968 CDC13 gene Proteins 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QVGLDPPIMKSVBG-UHFFFAOYSA-N 2-methylbutane Chemical compound CCC(C)C.CCC(C)C QVGLDPPIMKSVBG-UHFFFAOYSA-N 0.000 description 2
- 108010056388 Albunex Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- AZSZCFSOHXEJQE-UHFFFAOYSA-N dibromodifluoromethane Chemical compound FC(F)(Br)Br AZSZCFSOHXEJQE-UHFFFAOYSA-N 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 239000002961 echo contrast media Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229910052743 krypton Inorganic materials 0.000 description 2
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- DAFIBNSJXIGBQB-UHFFFAOYSA-N perfluoroisobutene Chemical group FC(F)=C(C(F)(F)F)C(F)(F)F DAFIBNSJXIGBQB-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002310 reflectometry Methods 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LANNRYWUUQMNPF-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)Br LANNRYWUUQMNPF-UHFFFAOYSA-N 0.000 description 1
- JQZFYIGAYWLRCC-UHFFFAOYSA-N 1-chloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)(F)Cl JQZFYIGAYWLRCC-UHFFFAOYSA-N 0.000 description 1
- BOUGCJDAQLKBQH-UHFFFAOYSA-N 1-chloro-1,2,2,2-tetrafluoroethane Chemical compound FC(Cl)C(F)(F)F BOUGCJDAQLKBQH-UHFFFAOYSA-N 0.000 description 1
- CYXIKYKBLDZZNW-UHFFFAOYSA-N 2-Chloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)CCl CYXIKYKBLDZZNW-UHFFFAOYSA-N 0.000 description 1
- OQNWUUGFAWNUME-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)propoxy]ethanol Chemical compound OCCOC(C)COCCO OQNWUUGFAWNUME-UHFFFAOYSA-N 0.000 description 1
- TZNJHEHAYZJBHR-UHFFFAOYSA-N 2-bromo-1,1,1-trifluoroethane Chemical compound FC(F)(F)CBr TZNJHEHAYZJBHR-UHFFFAOYSA-N 0.000 description 1
- KZRDDIMEUPJTAW-UHFFFAOYSA-N 2-n-carboxamidonormianserin Chemical compound C1C2=CC=CC=C2N2CCN(C(=O)N)CC2C2=CC=CC=C21 KZRDDIMEUPJTAW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- FUXMYCFDDGCLDT-ZHEIGUNKSA-N C(CCCCCCCCCCC)C1(O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO.[Na] Chemical compound C(CCCCCCCCCCC)C1(O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO.[Na] FUXMYCFDDGCLDT-ZHEIGUNKSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- WCQRWCFGZARAMR-UHFFFAOYSA-N [F].[F] Chemical compound [F].[F] WCQRWCFGZARAMR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- XQPRBTXUXXVTKB-UHFFFAOYSA-M caesium iodide Chemical compound [I-].[Cs+] XQPRBTXUXXVTKB-UHFFFAOYSA-M 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 101150094817 entB gene Proteins 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- ODNTYCQMAAGQTQ-UHFFFAOYSA-N pentane;pent-1-ene Chemical compound CCCCC.CCCC=C ODNTYCQMAAGQTQ-UHFFFAOYSA-N 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- 229950003332 perflubutane Drugs 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- -1 polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RZXZIZDRFQFCTA-UHFFFAOYSA-N teflurane Chemical compound FC(Br)C(F)(F)F RZXZIZDRFQFCTA-UHFFFAOYSA-N 0.000 description 1
- 229950010846 teflurane Drugs 0.000 description 1
- LXEJRKJRKIFVNY-UHFFFAOYSA-N terephthaloyl chloride Chemical compound ClC(=O)C1=CC=C(C(Cl)=O)C=C1 LXEJRKJRKIFVNY-UHFFFAOYSA-N 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- VPAYJEUHKVESSD-UHFFFAOYSA-N trifluoroiodomethane Chemical compound FC(F)(F)I VPAYJEUHKVESSD-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/924—Significant dispersive or manipulative operation or step in making or stabilizing colloid system
- Y10S516/929—Specified combination of agitation steps, e.g. mixing to make subcombination composition followed by homogenization
Abstract
This invention relates to an oil-in-water emulsion that is of a water-isoluble gas-forming chemical and a stabilizer, the emulsion being capable of forming microbubbles of gas upon application of ultrasonic energy. This composition allows for site-specific imaging as the image-enhancing bubbles can be released upon the application of ultrasonic energy at the specific location where the image is desired.
Description
.a~ s44 ~ o EMULSIONS AS CONTRAST AGENTS AND METHOD OF USE
Background of the Invention 1. Field of the Invention:
This invention relates to diagnostic ultrasonic imaging and contrast agents for use thereof. More particularly, it relates to ultrasonic contrast agents comprising emulsions capable of forming gas microbubbles upon the application of ultrasonic energy and methods for their use in diagnostic imaging.
Background of the Invention 1. Field of the Invention:
This invention relates to diagnostic ultrasonic imaging and contrast agents for use thereof. More particularly, it relates to ultrasonic contrast agents comprising emulsions capable of forming gas microbubbles upon the application of ultrasonic energy and methods for their use in diagnostic imaging.
2. Brief Description of the Hackcrround Art:
Diagnostic ultrasonic imaging is based on the principal that waves of sound energy can be focused upon an area of interest and reflected in such a way as to produce an image thereof. The ultrasonic scanner utilized is placed on a body surface overlying the area to be imaged, and sound waves are directed toward that area. The scanner detects reflected sound waves and translates the data into images. When ultrasonic energy is transmitted through a substance, the amount of energy reflected depends upon the velocity of the transmission and the acoustic properties of the substance. Changes in the substance's acoustic properties (e.g. variations in acoustic impedance) are most prominent at the interfaces of different substances, such as liquid-solid or liquid-gas. Consequently, when ultrasonic energy is directed through media, changes in acoustic properties will result c~~~~~~~
in more intense sound reflection signals for detection by the ultrasonic scanner.
Ultrasonic imaging agents of particular importance are composed of gas-containing substances which, when injected into the circulatory system, provide improved sound reflection and image clarity. One class of gas-containing imaging agents consists of microspheres of gas surrounded by a shell made of a biocompatible substance. These are best typified by ALBUNEX°
(Molecular Biosystems, San Diego, California: U.S. Patent Nos. 4,572,203; 4,718,433; 4,744,958; 4,844,882 and 4,957,656) which consists of microspheres of air surrounded by albumin shells. Another such microspheric imaging agent is described by Holmes et al. These microspheres consist of either non-proteinaceous crosslinked or polymerized amphipathic moieties forming micelles (PCT WO 92/17212) or crosslinked proteins (PCT
Diagnostic ultrasonic imaging is based on the principal that waves of sound energy can be focused upon an area of interest and reflected in such a way as to produce an image thereof. The ultrasonic scanner utilized is placed on a body surface overlying the area to be imaged, and sound waves are directed toward that area. The scanner detects reflected sound waves and translates the data into images. When ultrasonic energy is transmitted through a substance, the amount of energy reflected depends upon the velocity of the transmission and the acoustic properties of the substance. Changes in the substance's acoustic properties (e.g. variations in acoustic impedance) are most prominent at the interfaces of different substances, such as liquid-solid or liquid-gas. Consequently, when ultrasonic energy is directed through media, changes in acoustic properties will result c~~~~~~~
in more intense sound reflection signals for detection by the ultrasonic scanner.
Ultrasonic imaging agents of particular importance are composed of gas-containing substances which, when injected into the circulatory system, provide improved sound reflection and image clarity. One class of gas-containing imaging agents consists of microspheres of gas surrounded by a shell made of a biocompatible substance. These are best typified by ALBUNEX°
(Molecular Biosystems, San Diego, California: U.S. Patent Nos. 4,572,203; 4,718,433; 4,744,958; 4,844,882 and 4,957,656) which consists of microspheres of air surrounded by albumin shells. Another such microspheric imaging agent is described by Holmes et al. These microspheres consist of either non-proteinaceous crosslinked or polymerized amphipathic moieties forming micelles (PCT WO 92/17212) or crosslinked proteins (PCT
3), both of which encapsulate gasses such as nitrogen, SF6 and CF4.
Another class of ultrasonic imaging agents can be described as microparticles of a solid or semi-solid substance containing gas which is entrapped in the microparticle matrix during production. Glajich et al.
(U.S. Patent No. 5,147,631) describe the formation of porous particles of an inorganic material containing entrapped gas or liquid such as 02, CF4, perfluoroethane and argon. Erbel et al. (U. S. Patent No. 5,137,928) describe polyamino-dicarboxylic acid-co-imide derivatives capable of entrapping gasses such as air, argon and krypton. Albayrak et al. (European Patent Specification 0 357 163) describe crystalline complexes entrapping gasses such as nitrogen, krypton, SF6, cyclopropane and pentane which are dissolved in an aqueous vehicle such as protein or glycerol causing the release of gas bubbles.
The aqueous vehicle, now containing a plurality of T _.
WO 94128939 216 4 ~~ 1 0 p~IVS~4I05965 microbubbles of gas in solution,_is then ready for use as an-injectable ultrasonic imaging agent. stein et al.
!European Patent Specification 327 490) describe microparticlea containing amyloses or synthetic S biodegradable polymers entrapping gasses or liquids with a boiling point Less than 60°C.
Another class of gas-containing imaging agents are lipid vesicles Br liposomes. Unger (U. S. Patent Nos.
5,088,499 and 5,123,414) describes the encapsulation of ga$aes yr gaseous precursors in liposvmes, more particularly liposomee which contain ionophores for aCtivatlon of gaseous precursors by way of a pH gradient.
Render~on et al. !PCT WO 92/15824) describe lipid vesicles with gas-filled center cores.
iS still another class of imaging agents is -compoaed of microbubblee of ga$ in solution. For example. Tickner et al. (U.9. Patent No. 4,276,88S) describe microbubblee dispersed in liquitied gelatin_ More recently, Quay (pCT WO 93/05819) describes ultrasound imaging agents comprising microbubbles of selected gasses in solution. In a specific embodiment Quay describes the formation og a gas-liquid emulsion of decaEluorobutane_ Also disclosed therein are imaging agents comprising aqueous dispersion of biocompatible 2S gasses, some of which are gaseous at ambient temperature and others of which beevme gaseous at the body temperature .og the subject being imaged.
The efficiency of gas as an ultrasound imaging agent is described by J_ Ophir and K.J. Parker, Contrast Ac~entB in Dipqnpsti~ Ultraq~, Ultrasound in M~diCine and Biology (1989), Vol. iS(4) p. 319-333. However, the disadvantages of using gas as an ultrasound imaging agent have been and continue to be lacking of sufficient persistence of the gas in-vivo and in-vitro, and toxicity 35 due to the introduction of gas into the venous system.
WO 94/28939 2 16 4 410 PCT/US94/05965 .
Another class of ultrasonic imaging agents can be described as microparticles of a solid or semi-solid substance containing gas which is entrapped in the microparticle matrix during production. Glajich et al.
(U.S. Patent No. 5,147,631) describe the formation of porous particles of an inorganic material containing entrapped gas or liquid such as 02, CF4, perfluoroethane and argon. Erbel et al. (U. S. Patent No. 5,137,928) describe polyamino-dicarboxylic acid-co-imide derivatives capable of entrapping gasses such as air, argon and krypton. Albayrak et al. (European Patent Specification 0 357 163) describe crystalline complexes entrapping gasses such as nitrogen, krypton, SF6, cyclopropane and pentane which are dissolved in an aqueous vehicle such as protein or glycerol causing the release of gas bubbles.
The aqueous vehicle, now containing a plurality of T _.
WO 94128939 216 4 ~~ 1 0 p~IVS~4I05965 microbubbles of gas in solution,_is then ready for use as an-injectable ultrasonic imaging agent. stein et al.
!European Patent Specification 327 490) describe microparticlea containing amyloses or synthetic S biodegradable polymers entrapping gasses or liquids with a boiling point Less than 60°C.
Another class of gas-containing imaging agents are lipid vesicles Br liposomes. Unger (U. S. Patent Nos.
5,088,499 and 5,123,414) describes the encapsulation of ga$aes yr gaseous precursors in liposvmes, more particularly liposomee which contain ionophores for aCtivatlon of gaseous precursors by way of a pH gradient.
Render~on et al. !PCT WO 92/15824) describe lipid vesicles with gas-filled center cores.
iS still another class of imaging agents is -compoaed of microbubblee of ga$ in solution. For example. Tickner et al. (U.9. Patent No. 4,276,88S) describe microbubblee dispersed in liquitied gelatin_ More recently, Quay (pCT WO 93/05819) describes ultrasound imaging agents comprising microbubbles of selected gasses in solution. In a specific embodiment Quay describes the formation og a gas-liquid emulsion of decaEluorobutane_ Also disclosed therein are imaging agents comprising aqueous dispersion of biocompatible 2S gasses, some of which are gaseous at ambient temperature and others of which beevme gaseous at the body temperature .og the subject being imaged.
The efficiency of gas as an ultrasound imaging agent is described by J_ Ophir and K.J. Parker, Contrast Ac~entB in Dipqnpsti~ Ultraq~, Ultrasound in M~diCine and Biology (1989), Vol. iS(4) p. 319-333. However, the disadvantages of using gas as an ultrasound imaging agent have been and continue to be lacking of sufficient persistence of the gas in-vivo and in-vitro, and toxicity 35 due to the introduction of gas into the venous system.
WO 94/28939 2 16 4 410 PCT/US94/05965 .
The present invention relates to site specific oit-in-water emulsions and is based on the unexpected observation that emulsions of gas-forming chemicals can be stabilized in the liquid state and will produce microbubbles when subject to ultrasonic energy. The advantages are that such emulsions are more stable than most of the gas-containing imaging agents heretofore described, and their ability to form microbubbles when subject to ultrasonic energy makes them site-specific and inherently less toxic due to less overall gas being introduced into the venous system.
~ummarv of the Invention This invention provides an emulsion which can be used as an ultrasonic imaging agent. The emulsion is made of at least one water-insoluble gas-forming chemical and at least one stabilizer. This emulsion is capable of forming microbubbles of gas upon application of ultrasonic energy. The stabilizer is either a hydrophobic or amphipathic compound having a boiling point higher than that of the gas-forming chemical and, when present in the emulsion with the gas-forming chemical, acts as a stabilizer (maintains the gas-forming chemical in the liquid state) until the application of ultrasonic energy. The stabilizer causes the effective boiling point of the gas-forming chemical to be raised thereby preventing the volatilization of the gas-forming chemical until it reaches a temperature above its boiling point at atmospheric pressure (760 nm). In this way, upon application of ultrasonic energy, the emulsified chemical becomes volatilized and produces gas microbubbles. In a specific embodiment the water-insoluble gas-forming chemical is perfluoropentane and the stabilizer is lecithin. This invention also provides additional means to stabilize the emulsion for delivery ~~. ~4~ ~. D
~ummarv of the Invention This invention provides an emulsion which can be used as an ultrasonic imaging agent. The emulsion is made of at least one water-insoluble gas-forming chemical and at least one stabilizer. This emulsion is capable of forming microbubbles of gas upon application of ultrasonic energy. The stabilizer is either a hydrophobic or amphipathic compound having a boiling point higher than that of the gas-forming chemical and, when present in the emulsion with the gas-forming chemical, acts as a stabilizer (maintains the gas-forming chemical in the liquid state) until the application of ultrasonic energy. The stabilizer causes the effective boiling point of the gas-forming chemical to be raised thereby preventing the volatilization of the gas-forming chemical until it reaches a temperature above its boiling point at atmospheric pressure (760 nm). In this way, upon application of ultrasonic energy, the emulsified chemical becomes volatilized and produces gas microbubbles. In a specific embodiment the water-insoluble gas-forming chemical is perfluoropentane and the stabilizer is lecithin. This invention also provides additional means to stabilize the emulsion for delivery ~~. ~4~ ~. D
to a patient. These means include delivery vehicles such as a natural polymer matrix, a synthetic polymer matrix or a liposome. More specifically, it is provided that the natural polymer matrix is an albumin matrix. This albumin matrix can be derivatized to contain polyethylene glycol.
This invention also provides a method to enhance the contrast of tissues and organs in an ultrasonic image comprising: (a) injecting at least one stabilized water-insoluble gas-forming chemical into a patient; (b) applying a sufficient amount of ultrasonic energy to volatilize said chemicals to release microbubbles; and (c) detecting an ultrasonic image. The water-insoluble gas-forming chemical is stabilized with a hydrophobic or amphipathic stabilizer.
Brief Description of the Drawing's.
Fig. lA shows the effects of increasing ultrasonic energy transmit power on reflectivity of the ultrasonic signal (expressed as video brightness) in the presence of an ALHUNEX~ (Molecular Biosystems, San Diego, California) sample.
Fig. 1H shows the effects as descried in Fig.
lA in the presence of the perfluoropentane emulsion of Example 1.
Fig-2 shows the difference in video brightness observed when the emulsion of Example 5 is either continually exposed to ultrasonic energy, or exposed only during 30 second intervals every 5 minutes.
Fig-3 shows the difference in video brightness observed when Emulsion C of Example 7 is either continually exposed to ultrasonic energy, or exposed only during 30 second intervals every 5 minutes.
Fig. 4 shows the 1H NMit spectrum of a CDC13 solution of nonafluoro-t-butylmethane (C4F9CH3).
This invention also provides a method to enhance the contrast of tissues and organs in an ultrasonic image comprising: (a) injecting at least one stabilized water-insoluble gas-forming chemical into a patient; (b) applying a sufficient amount of ultrasonic energy to volatilize said chemicals to release microbubbles; and (c) detecting an ultrasonic image. The water-insoluble gas-forming chemical is stabilized with a hydrophobic or amphipathic stabilizer.
Brief Description of the Drawing's.
Fig. lA shows the effects of increasing ultrasonic energy transmit power on reflectivity of the ultrasonic signal (expressed as video brightness) in the presence of an ALHUNEX~ (Molecular Biosystems, San Diego, California) sample.
Fig. 1H shows the effects as descried in Fig.
lA in the presence of the perfluoropentane emulsion of Example 1.
Fig-2 shows the difference in video brightness observed when the emulsion of Example 5 is either continually exposed to ultrasonic energy, or exposed only during 30 second intervals every 5 minutes.
Fig-3 shows the difference in video brightness observed when Emulsion C of Example 7 is either continually exposed to ultrasonic energy, or exposed only during 30 second intervals every 5 minutes.
Fig. 4 shows the 1H NMit spectrum of a CDC13 solution of nonafluoro-t-butylmethane (C4F9CH3).
Fiq. 5 shows the 19F NNfft spectrum of a CDC13 solution of nonafluoro-t-butylmethane (C4F9CH3).
Detailed Description of the Invention We have now found that particularly effective site-specific ultrasonic contrast agents may be obtained by preparing emulsions of water-insoluble gas-forming chemicals. These gas-forming chemicals are stabilized by emulsification with a stabilizer. Additionally, the emulsification of the gas-forming chemicals, which are for the most part insoluble in water, serves to make the contrast agent more soluble and thus administrable to a patient. The water-insoluble gas-forming chemical must be capable of forming gas at the body temperature of the animal being imaged and will generally have a boiling point below body temperature. As discussed herein, boiling point will refer to the temperature at which the thermal energy of the molecules of a chemical are great enough to overcome the cohesive forces that hold them together in a liquid state (or solid state for chemicals which sublime and thus have no liquid state) at atmospheric pressure (760 nm). A stabilizer having a boiling point higher than that of the gas-forming chemical is necessary to stabilize the gas-forming chemical in the liquid state until the application of ultrasonic energy. The stabilizer causes the temperature at which the gas-forming chemical volatilizes to a gas to be raised to a temperature above its boiling point. In this way, the gas-forming chemical is actually both stabilized (maintained in a liquid state above its boiling point) and destabilized (capable of being volatilized upon exposure to ultrasonic energy) simultaneously. When the emulsion of the present invention is volatilized by exposure to ultrasonic energy, such as 50% transmit power at 5.0 Ngiz, gas _7_ microbubbles are formed and released from the emulsion thereby increasing the ultrasonic reflectivity in the area being imaged.
The water-insoluble gas-forming chemicals useful in the present invention can be further characterized as being non-toxic, physiologically compatible and generally having a boiling point below 37°C, and preferably between 26°C and 34°C. Some of the gas-forming chemicals which would be useful in the present invention and their boiling points at atmospheric pressure are:
Gas-forming Chemical Roiling Point C
pentane 1-pentene 30 perfluoropentane 29.5 2-methyl butane (isopentane) 27.8 tetramethylsilane 26 2-bromo-1,1,1-trifluoroethane 26 dibromodifluoromethane 25 fluorotrichloromethane 24 2 H-perfluoro-t-butane 13 cyclobutane 12 heptafluoropropylbromide 12 1-chloro-1,1,2,2-tetrafluoroethane 10.2 neopentane 9,5 teflurane 2-chloro-1,1,1-trifluoroethane 6.g decafluorobutane 4 butane -0.5 2-chloro-1,1,1,2-tetrafluoroethane -12 2 H-heptafluoropropane -15 iodotrifluoromethane -22.5 cyclopropane -33 wv 94128939 216 4 410 ~'T~S94~as9~s perfluoroethyla~nine . - 3 5 octafluoropropane -36 SF6 (sulrur hexafluoride) -&4 The stabilizer of the present invention may be a hydrophobic or amphipathic (containing both hydrophobic and hydrophilic entities) compound. Hydrophobic compounds include di- and triglycerides; saturated and unsaturated hydrocarbons; perfluorocarbons such as perfluorohexane or perfluorodecalin; gate and fatty oils such as trivlein.
Amphipathic compounds include phospholipids such ae phvaphatidic acid, phosphatidylglycerol, and phoephatidylinoaitol; alkali salts of fatty acids; ionic aurractants such as sodium dodecyl sulfate; non-ionic surfactants Such ae PLURONIC~ F-68 (trade name for pvloxamer 188, a block copolymer ot.polyoxyethylene and polyoxypropylene (CAS-9003-11-6) HD (CH2CHa0) n ('CHCH20) p (CH2CH20) nH
~3 whorein the average value of n~~5 and the average value of p-3o such that the average molecular weight of said compound is 8350 daltons) and polysorbate 80; zwitterionic surfactants such ae phoaphatidylcholine tlecithin), phosphatidylethanolamine and phosphatidylserine; amino acid polymers or proteins with hydrophilic and hydrophobic moieties such ag albumin.
Amphipathic compounds which are particularly useful a.s stabilizers of fluorinated gas-forming compounds are themselves rluorinated. TheBe compounds act ae both stabilizers and solubilizerg of fluorinated gas-forming compounds, due to the fluorine-fluorine interactions between the two compounds. Such fluvrirated stabilizers generally have a hydrvphobiC fluorocarbon B
,:,;
_g_ chain connected to a hydrophilic moiety, such as a pol.yether, sugar, carbvxylate, sulfonate or a quaternary ammonium group. Examples of fluorinated stabilizers can be found in U.S. Patent Nos. 5,077,036, 5,080,855 and 4,987,154.
When the boiling point of the gas-forming chemical is below the temperature at which the emulsion is prepared and stored, such as less than 24°C, it is still possible to form a liquid-liquid oiI-in-water emulsion of the present invention by using a stabilizer which is capable of strong hydrophobic interactions with the gas-forming chemical which will maintain the gas-gvrming chemical in a liquid state above its boiling point. particularly useful stabilizers for this purpose are C5 to C20 pertluorocarbons or hydrocarbons and can be either hydrophobic or amphipathic.
The stabilizer may be used singly or in various combinations in the emul8ions of the present invention.
However, when the stabilizer is a hydrophobic compound, it will be necessary to also have present a surface active agent either within the emulsion or in association with the emul8ion in order for the emulsion to be soluble and thus physiologically tolerated. Surface active agents, or surfactants, are characterized as being substances that lower the surface tension between two liquids. A surface active agent will generally be an amphipathic Compound as described above or may also be a cationic or anionic compound. Additionally, a surfactant and a co-surfactant combination, such as phvephatidyl choline and PLURONIC~ F-68 is also contemplated.
When the stabilizer is amphipathic, the presence of an additional hydrophobic compound is generally not necessary. zn particular, the chemical 3S PLURONIC~ F-68 has been found tv surticiently aolubilize WO 94/28939 216 4 410 PCT~S94/05965 and stabilize the gas-forming chemical in the absence of an additional hydrophobic compound.
The amount of stabilizer present in the emulsion of the present invention will vary over a wide range of concentrations depending on the concentration and properties of the other components of the emulsion and will be principally dependent on the amount and characteristics of the,gas-forming chemical. This is exemplified in the example section.
Optionally present in the emulsion are viscosifiers which are generally polyalcohols or carbohydrates such as glycerol, sorbitol, lactose, sucrose and dextrans, and preferably glycerol at a concentration between 5-15% (w/v). Other optional constituents are anti-oxidants such as a-tocopherol, preferably at a concentration of 0.1 to 0.25% (w/v).
Still another class of optional components are compounds which impart organ or tissue target specificity to the emulsion. These compounds may include steroids such as cholesterol, proteins, lipoproteins and antibodies.
The emulsion of the present invention may be useful as an ultrasonic imaging agent either by itself or in combination with a delivery vehicle which may be used to impart greater stability, both in-vivo and in-vitro, or tissue or organ target specificity. One such delivery vehicle can be made from a natural polymer which forms a matrix, such as an albumin matrix, with multiple chambers which contain the emulsion of a gas-forming chemical.
The surface of the albumin matrix so described may also be modified to contain a polymer such as polyethylene glycol to reduce reticular endothelial system uptake in vivo.
Further examples of delivery vehicles comprise the use of synthetic polymers, such as the polyamino dicarboxylic acid-co-imide derivatives disclosed in U.S.
WO 94/28939 2 16 4 4 l 0 ~~US94~05965 Patent No. 5,190,982 or the crosslinkable synthetic polymers such ag pvlyphoaphazinea de9cribes in U.8_ Patent No. S,I49,543, Another delivery vehicle may comprise a liposome. In addition to the delivery vehicles described, it is understood that any delivery vehicle designed to make hydrophobic compounds, whether they are therapeutic or diagnostic compounds, administrable to a patient is also cvntemplated_ The emulsions of the present invention, whether or not they are incorporated into a delivery vehicle, will generally have a size below 8.0 ~C, and preferably below 5.0 ~,c. It is additionally anticipated that microemulsions can be prepared according tv the pre9ent IS invention with a size below I.0 ~.
~rtu~u~rtrt~ t An emulsion useful for stabilizing the gas-forming chemical wag made by mixing the following components together by rotating under vacuum_ Glycerol,Trioleate (triolein) 1.25 g 1.2-dioleoyl-glycero-3-phosphvcholine 15 (20 mg/ml in chlvrofozm) cholesterol 0.05 g a-tocopherol 0.012 g Any remaining solvent was removed by drying under high vacuum at room temperature (20-2S°C)_ After 16 hours, 1.58 g of glycerol (1.26 g/ml) and 0.2 g perfluoropentane were added. Then, 9.6 m1 of water were added slowly while mixing at 10,000 rpm in a POLXTRON~
PT3000 (Hrin.k~nan, We9tbury, New York) for 2 minutes at 0°C. The resultant emu181on was further homogeni2ed for 3 minutes at 30,000 rpm.
t,t~., WO 94128939 216 4 410 PCTIUS94l05965 The ultrasonic imaging characteristics of the emulsion of Example 1 where studied using an HP SONOS 100 Ultrasound Imaging system (Hewlett-Packard, Palo Alto, California) with a 5 IrBiz transducer (focal zone = 3.5 cm) in sector mode to detect the scattering capability of the sample solution_ The compression was adjusted to obtain the greatest dynamic range possible, i.e. 60 d8. The time gain compensation control of the ultrasound system to was adjusted until the image sector being imaged ie judged visually to be optimal.
The imaging sequence was started by optimizing the instrument as described in 1.0 L of water at 37°C at transmit power. A 1.0 ml sample was then injected into the Water. Thereafter, every 2 minutes the transmit power was adjusted upwardB to 10, 20, 30, ~0, 50, 60, 70, 80, 90 and 99ic. The entire sequence of images was recorded on videotape (attached to the ultrasound system) for storage and analysis.
To prepare quantitative results of this experiment, videodensitometry analysis was performed.
Selected video frames stored on the videotape were digitized using an Apple Macintosh zh~computer equipped with a Data Translation QuickCapture~frame grabber board.
These frames were analyzed using CineProbe~ version 2.0 (Molecular Hioeyatems, San Diego, California) image processing software. A Region of Interest (ROI) within the beaker was selected and the mean pixel intensity (video brigritneee) within the region was determined.
Each frame was then analyzed as to its mean videodenaicy within the region of interest. The videodensity of a water blank is subtracted and the resultant videodensity is expressed as Video Hrightness yr Normalized Video Brightness when the initial value is set to 100 for comparison.
*Trade-mark WO 94!7,.8939 216 4 410 PCT/US9~110596s An ALHUNEX~ (MoleCUlar_Biasyatema, Ban Diego, California) (micrebubbles surrounded by a protein shell prepared as described in U.S. Patent Noa. 4,572,203;
4,718,433; 4,744,958; 4,844,882 and 4,957,656) control was also prepared and analyzed as described by injecting a 1.0 mL sample of ALHUNEXm (Molecular Hioeystems, San Diego, California) into 1.0 liter of 37°C water_ The results of this experiment are depicted in Figure lA and 1H. Due to the unchanging number of l0 microbubbles present in the ALBUNEX~ (Molecular Hiosystems, San. Diego, California) sample, there would be expected to be a linear relationship between transmit power and video brightness. This linear relationship is depicted in Pigure lA. In.comparison, using the emulsion of Example 1, there would be the expectation of a bilinear or step Lunction between video brightness and transmit power which would be due to some threshold energy of cavitation for micrvbubblea to be formed upon exposure to ultrasonic energy Such a relationship was observed, and these results are depicted in Figure IH.
The following components were added together and homogenized in the POLYTROtHm (Hrinkman, Westbury, New York) at 0°C for 3 minutes at 10,000 rpm while slowly adding 10 ml ultrapure water:
Trialein 0.6 g Glycerol 1.57 g Lecithin 0.6 g Pertluoropentane 1.5 g These components were further homogenized for an additional 2 minutes at 30,000 rpm to produce a milky white emulei.an. This emulsion was filtered successively thxough a 5 P. and 1.2 ~ filter. The particle size was determined in a Nicomp 770*(Particle Sizing Systems, *Trade-mark WO 94/28939 216 4 410 pCT/LTS94/05965 Santa Barbara, California) to be 95% less than 3.8 ~,. It was stable (no appreciable phase separation or particle size increase) for several days at 4°C. When imaged as described in Example 2, this emulsion demonstrated microbubble formation above 40% transmit power as observed in the ultrasonic image.
The following components were added together and homogenized in the POLYTRON~ (Brinkman, Westbury, New York) at 0°C for 3 minutes at 10,000 while slowly adding ml water:
Triolein 1.0 g Glycerol 1.0 g 15 a-Tocopherol 0.02 g PLURONIC~ F-68 0.2 g Gas-forming Chemical 1.5 g of one of the following:
Emulsion A: FCC13 (Fluorotrichloromethane) 20 Emulsion H: Br2F2C (Dibromodifluoromethane) Emulsion C: TMS (Tetramethylsilane) Emulsion D: 2-Methyl butane (Isopentane) The above emulsions were filtered through a 1.2 ~, filter and the particle sizes were determined as described in Example 4 to be:
A 95% less than 2.97 H 95% less than 4.02 C 95% less than 2.18 D 95% less than 2.99 ~C
The following components were added together and homogenized in the POLYTRON~ (Brinkman, Westbury, New York) at 0°C for 5 minutes at 10,000 rpm while slowly adding 20 ml water:
WO 94/28939 216 4 410 pCT/US94/05965 Triolein 1.0 g Glycerol 3.0 g a-Tocopherol 0.02 g Lecithin 1.0 g Perfluoropentane 1.0 g The emulsions were further homogenized for 3 minutes at 20,000 rpm and filtered successively through a 5 ~, and 1.2 ~, filter. The ultrasonic imaging characteristics of the emulsion were studied as described in Example 2 and exhibited microbubble formation above 40% transmit power as observed in the ultrasonic image.
To further study the effects of ultrasonic energy on the production of microbubbles, the emulsion of Example 5 (perfluoropentane) was imaged in two separate experiments either continually or in 30 second intervals.
For each experiment, a 1.0 ml sample of the emulsion was added to 1.0 liter of water at 37°C. In the first experiment, ultrasonic imaging as described in Example 2 was carried out at 99% transmit power continuously for 30 minutes. In the second experiment, the ultrasonic imaging was carried out for 30 second durations once every 5 minutes (intermittent imaging). Image brightness was quantified as described in Example 2 and the results are depicted in Figure 2. These results demonstrate that with continuous ultrasonic energy, due to the constant production of microbubbles and depletion of the bubble-forming capability of the emulsion, image brightness was significantly diminished at the end of 30 minutes. In comparison, with intermittent imaging which exposed the emulsions to only one-tenth the energy as compared to constant imaging (30 seconds every 5 minutes), the microbubble-forming capability of the emulsion persisted WO 94/28~'" 2 ~ 6 4 410 PCT/US94/05965 and a substantial amount of microbubbles continued to be produced even after 30 minutes.
An alternative emulsion formulation comprises a viscosifier, a stabilizer which is amphipathic and a gas-forming chemical formed by mixing together the following components in a final volume of 50 mL water:
Viscosifier: Stabilizer:
Emulsion A PLURONIC° F-68 Sucrose (8.6 g) (0.5 g) Emulsion B Sodium dodecyl- Sucrose (8.6 g) sulfate (1.44 g) Emulsion C PLURONIC° F-68 Lactose (9.0 g) (0.5 g) Emulsion D Sodium dodecyl- Lactose (9.0 g) sulfate (1.44 g) The solutions from above were filtered through a 0.2 ~, filter. A 10 mL aliquot of each of the above were mixed with 0.168 mL of perfluoropentane in the POLYTRON° (Brinkman, Westbury, New York) at 0°C for 1 to 3 minutes at 10,000 to 20,000 rpm and then for an additional 5 minutes at 20,000 rpm. Each of these four emulsions demonstrated microbubble formation as observed in the ultrasonic image above 40% transmit power when studied as described in Example 2.
To study the effects on these emulsions of continuous versus intermittent exposure to ultrasonic energy, a 1.0 mL sample of Emulsion C was placed in 1.0 liter of degassed water at 37°C. This solution was ultrasonically imaged either continuously or in intervals as described in Example 6. The results are depicted in Figure 3.
SYNTHESIS OF NONAFLUORO-t-BUTYL METHANE C4F9CH3 Starting materials (methyl iodide and cesium fluoride) were obtained from Aldrich Chemical Company and perfluoroisobutylene gas was obtained from Flura Corporation. Nuclear magnetic resonance spectra were obtained using a 200 MHz instrument tuned for determination of proton (1H) or fluorine (19F) resonances.
In a flask equipped with a gas inlet, mechanical stirrer and a dry ice condenser was placed a suspension of dry cesium fluoride (42.5 g, 0.279 mol) in diglyme (200 mL). Perfluoroisobutylene gas (55.5 g, 0.278 mol) was bubbled in. The gas reacted rapidly with cesium fluoride and a yellow solution resulted. The mixture was stirred for 30 minutes and then methyl iodide (38.5 g, 0.271 mol) was added dropwise. The reaction was slightly exothermic and the cesium iodide separated out.
The mixture was stirred for 3 hours and was allowed to stand overnight. A cold solution (2M, sodium chloride, 500 mL) was added to the mixture with cooling (5°C) for minutes. Sodium iodide and most of the diglyme solvent dissolved in the aqueous phase which was then decanted off from the solid giving a crude yield of 45 g 25 ( 40%). Distillation of the compound sublimed at head temperature 35-39°C and bath temperature not exceeding 50-55°C. The product was collected in a receiver cooled to -30°C with dry ice and ethanol. The proton 1H NMR
spectrum of its CDC13 solution showed a single resonance 30 relative to TMS; 1.65 (s, 3H, CH3) ppm (see Figure 4) and the 19F spectrum, in the same solvent, showed also one single resonance at -69.99 (s, 9F) ppm relative to CDC13 (see Figure 5).
NONAFLUORO-t-BUTYL METHANE C4F9CH3 is shown according to either of the following chemical formulas:
F
I
F-C - F
CFs F F
I I
F-C C C -F
FsC - C - CFs I I
F ~ F
CHs H-C.-H
I
H
The following components were mixed together and homogenized in the POLYTRON~ (Hrinkman, Westbury, New York) at 0°C for 3 minutes at 10,000 rpm while slowly adding 10 mL ultrapure water.
Triolein 1.01 g Glycerol 1.05 g cx-Tocopherol 0.02 g PLURONIC~ F-68 0.099 g C4F9CH3 0.780 g The resultant emulsion was filtered through a 5 ~. filter. The particle size was determined as described in Example 4 to be less than 4.30 microns.
The ultrasonic imaging characteristics of the 2'S emulsion were studied as described in Example 2. The formation of gas bubbles was observed even at low transmit power (<25%) settings which became brighter as the transrnit power was slowly increased to 99%.
Also for comparison a control experiment without C4F9CH3 was conducted by mixing the following components:
Triolein 1.01 g Glycerol 1.05 g a-Tocopherol 0.021 g PLURONIC° F-68 0.204 g I . ..._. . __ v VYO 94IZ8939 216 4 41 Q ~CT~US9di05965 The emulsion was prepared as described above.
In contrast to the pxevioua ultrasound imaging experiment, micropubble formation was not observed even at 99~ transmit power.
F~BM~E .10 The Following components were added together and homogenized in the P4LYTRON~ (Brinlanan, Westbury, New York) at 0°C for 2 minutes at 10,000 rpm while slowly adding 10 ml water:
Triolein 1_0 g Glycerol I.0 g a-Tocvpherol 0.03 g PLURONIC~ F-68 0_1 g 1$ Isvpentane 0.15 g n-Pentane 0_85 g The emulsion was further homogenized for 6 minutes at 30,000 rpm and filtered through a 1.2 filter. The ultrasonic imaging characteristics of the emulsion were studied ae described in Example 6 and a higher level v~ video brightness was observed with intermittent imaging than with continuous imaging.
EMULSION-CONTAININC3 ALBUMIN MICRaPARTZCLE
The emulsion of the present invention can be encapsulated into a delivery vehicle comprising a multi-chamber albumin matrix as follows:
A primary emulsion is prepared by first dissolving 2.0 g human aenim albumin in 20.0 ml buffer (0.45 N Na2C03, pH 9.8) and then adding I.0 g perfluoropentane. This mixture ie emulsified in an osteriaer*at high speed for 10 rninutee.
*Trade-mark tV0 94/x.8939 216 4 4 i 0 ~r/US94/DSg65 A double emulsion is then prepared by adding 100 ml Chloroform:Cyclohexane (1:4 v/v) with L0~ (v/v) sorbitan trioleate with continued mixing for 10 minutes.
The albumin is croeslinked by adding, while continuing to mix, an additional 100 m3 Chlorofozm:
Cyclohexane (1:4 v/v) containing 2.5 g terephthaloyl chloride and continuing to mix for an additional 30 minutes. The reaction is quenched with X00 mL of cyclohexane containing Sg polysorbate and 10~
(v/v) ethanolamine. The micrvcapsules are washed 3 times with cyclohexane:ethanol (i:i v/v), followed by 2 wa$hea in S~ polyavrbate-95~ ethanol, 2 washes in 95~ ethanol and a washes in water. The microparticles are then resuapended in normal saline and comprise multi-chambered vesicles containing an inner emulsiLied matrix of perfluoropentane.
Although the invention has been described primarily in connection with special and preferred embodiments, it will be u~derstvod that it is capable of modiLication without departing from the scope of the invention. The following claims are intended to cover all variations, uses or adaptations of the invention, following, in general, the principles thereof and including such departures from the present disclosure as come within known or customary practice in the field to which the invention pertains, or as are obvious to persons skilled in the art.
B
Detailed Description of the Invention We have now found that particularly effective site-specific ultrasonic contrast agents may be obtained by preparing emulsions of water-insoluble gas-forming chemicals. These gas-forming chemicals are stabilized by emulsification with a stabilizer. Additionally, the emulsification of the gas-forming chemicals, which are for the most part insoluble in water, serves to make the contrast agent more soluble and thus administrable to a patient. The water-insoluble gas-forming chemical must be capable of forming gas at the body temperature of the animal being imaged and will generally have a boiling point below body temperature. As discussed herein, boiling point will refer to the temperature at which the thermal energy of the molecules of a chemical are great enough to overcome the cohesive forces that hold them together in a liquid state (or solid state for chemicals which sublime and thus have no liquid state) at atmospheric pressure (760 nm). A stabilizer having a boiling point higher than that of the gas-forming chemical is necessary to stabilize the gas-forming chemical in the liquid state until the application of ultrasonic energy. The stabilizer causes the temperature at which the gas-forming chemical volatilizes to a gas to be raised to a temperature above its boiling point. In this way, the gas-forming chemical is actually both stabilized (maintained in a liquid state above its boiling point) and destabilized (capable of being volatilized upon exposure to ultrasonic energy) simultaneously. When the emulsion of the present invention is volatilized by exposure to ultrasonic energy, such as 50% transmit power at 5.0 Ngiz, gas _7_ microbubbles are formed and released from the emulsion thereby increasing the ultrasonic reflectivity in the area being imaged.
The water-insoluble gas-forming chemicals useful in the present invention can be further characterized as being non-toxic, physiologically compatible and generally having a boiling point below 37°C, and preferably between 26°C and 34°C. Some of the gas-forming chemicals which would be useful in the present invention and their boiling points at atmospheric pressure are:
Gas-forming Chemical Roiling Point C
pentane 1-pentene 30 perfluoropentane 29.5 2-methyl butane (isopentane) 27.8 tetramethylsilane 26 2-bromo-1,1,1-trifluoroethane 26 dibromodifluoromethane 25 fluorotrichloromethane 24 2 H-perfluoro-t-butane 13 cyclobutane 12 heptafluoropropylbromide 12 1-chloro-1,1,2,2-tetrafluoroethane 10.2 neopentane 9,5 teflurane 2-chloro-1,1,1-trifluoroethane 6.g decafluorobutane 4 butane -0.5 2-chloro-1,1,1,2-tetrafluoroethane -12 2 H-heptafluoropropane -15 iodotrifluoromethane -22.5 cyclopropane -33 wv 94128939 216 4 410 ~'T~S94~as9~s perfluoroethyla~nine . - 3 5 octafluoropropane -36 SF6 (sulrur hexafluoride) -&4 The stabilizer of the present invention may be a hydrophobic or amphipathic (containing both hydrophobic and hydrophilic entities) compound. Hydrophobic compounds include di- and triglycerides; saturated and unsaturated hydrocarbons; perfluorocarbons such as perfluorohexane or perfluorodecalin; gate and fatty oils such as trivlein.
Amphipathic compounds include phospholipids such ae phvaphatidic acid, phosphatidylglycerol, and phoephatidylinoaitol; alkali salts of fatty acids; ionic aurractants such as sodium dodecyl sulfate; non-ionic surfactants Such ae PLURONIC~ F-68 (trade name for pvloxamer 188, a block copolymer ot.polyoxyethylene and polyoxypropylene (CAS-9003-11-6) HD (CH2CHa0) n ('CHCH20) p (CH2CH20) nH
~3 whorein the average value of n~~5 and the average value of p-3o such that the average molecular weight of said compound is 8350 daltons) and polysorbate 80; zwitterionic surfactants such ae phoaphatidylcholine tlecithin), phosphatidylethanolamine and phosphatidylserine; amino acid polymers or proteins with hydrophilic and hydrophobic moieties such ag albumin.
Amphipathic compounds which are particularly useful a.s stabilizers of fluorinated gas-forming compounds are themselves rluorinated. TheBe compounds act ae both stabilizers and solubilizerg of fluorinated gas-forming compounds, due to the fluorine-fluorine interactions between the two compounds. Such fluvrirated stabilizers generally have a hydrvphobiC fluorocarbon B
,:,;
_g_ chain connected to a hydrophilic moiety, such as a pol.yether, sugar, carbvxylate, sulfonate or a quaternary ammonium group. Examples of fluorinated stabilizers can be found in U.S. Patent Nos. 5,077,036, 5,080,855 and 4,987,154.
When the boiling point of the gas-forming chemical is below the temperature at which the emulsion is prepared and stored, such as less than 24°C, it is still possible to form a liquid-liquid oiI-in-water emulsion of the present invention by using a stabilizer which is capable of strong hydrophobic interactions with the gas-forming chemical which will maintain the gas-gvrming chemical in a liquid state above its boiling point. particularly useful stabilizers for this purpose are C5 to C20 pertluorocarbons or hydrocarbons and can be either hydrophobic or amphipathic.
The stabilizer may be used singly or in various combinations in the emul8ions of the present invention.
However, when the stabilizer is a hydrophobic compound, it will be necessary to also have present a surface active agent either within the emulsion or in association with the emul8ion in order for the emulsion to be soluble and thus physiologically tolerated. Surface active agents, or surfactants, are characterized as being substances that lower the surface tension between two liquids. A surface active agent will generally be an amphipathic Compound as described above or may also be a cationic or anionic compound. Additionally, a surfactant and a co-surfactant combination, such as phvephatidyl choline and PLURONIC~ F-68 is also contemplated.
When the stabilizer is amphipathic, the presence of an additional hydrophobic compound is generally not necessary. zn particular, the chemical 3S PLURONIC~ F-68 has been found tv surticiently aolubilize WO 94/28939 216 4 410 PCT~S94/05965 and stabilize the gas-forming chemical in the absence of an additional hydrophobic compound.
The amount of stabilizer present in the emulsion of the present invention will vary over a wide range of concentrations depending on the concentration and properties of the other components of the emulsion and will be principally dependent on the amount and characteristics of the,gas-forming chemical. This is exemplified in the example section.
Optionally present in the emulsion are viscosifiers which are generally polyalcohols or carbohydrates such as glycerol, sorbitol, lactose, sucrose and dextrans, and preferably glycerol at a concentration between 5-15% (w/v). Other optional constituents are anti-oxidants such as a-tocopherol, preferably at a concentration of 0.1 to 0.25% (w/v).
Still another class of optional components are compounds which impart organ or tissue target specificity to the emulsion. These compounds may include steroids such as cholesterol, proteins, lipoproteins and antibodies.
The emulsion of the present invention may be useful as an ultrasonic imaging agent either by itself or in combination with a delivery vehicle which may be used to impart greater stability, both in-vivo and in-vitro, or tissue or organ target specificity. One such delivery vehicle can be made from a natural polymer which forms a matrix, such as an albumin matrix, with multiple chambers which contain the emulsion of a gas-forming chemical.
The surface of the albumin matrix so described may also be modified to contain a polymer such as polyethylene glycol to reduce reticular endothelial system uptake in vivo.
Further examples of delivery vehicles comprise the use of synthetic polymers, such as the polyamino dicarboxylic acid-co-imide derivatives disclosed in U.S.
WO 94/28939 2 16 4 4 l 0 ~~US94~05965 Patent No. 5,190,982 or the crosslinkable synthetic polymers such ag pvlyphoaphazinea de9cribes in U.8_ Patent No. S,I49,543, Another delivery vehicle may comprise a liposome. In addition to the delivery vehicles described, it is understood that any delivery vehicle designed to make hydrophobic compounds, whether they are therapeutic or diagnostic compounds, administrable to a patient is also cvntemplated_ The emulsions of the present invention, whether or not they are incorporated into a delivery vehicle, will generally have a size below 8.0 ~C, and preferably below 5.0 ~,c. It is additionally anticipated that microemulsions can be prepared according tv the pre9ent IS invention with a size below I.0 ~.
~rtu~u~rtrt~ t An emulsion useful for stabilizing the gas-forming chemical wag made by mixing the following components together by rotating under vacuum_ Glycerol,Trioleate (triolein) 1.25 g 1.2-dioleoyl-glycero-3-phosphvcholine 15 (20 mg/ml in chlvrofozm) cholesterol 0.05 g a-tocopherol 0.012 g Any remaining solvent was removed by drying under high vacuum at room temperature (20-2S°C)_ After 16 hours, 1.58 g of glycerol (1.26 g/ml) and 0.2 g perfluoropentane were added. Then, 9.6 m1 of water were added slowly while mixing at 10,000 rpm in a POLXTRON~
PT3000 (Hrin.k~nan, We9tbury, New York) for 2 minutes at 0°C. The resultant emu181on was further homogeni2ed for 3 minutes at 30,000 rpm.
t,t~., WO 94128939 216 4 410 PCTIUS94l05965 The ultrasonic imaging characteristics of the emulsion of Example 1 where studied using an HP SONOS 100 Ultrasound Imaging system (Hewlett-Packard, Palo Alto, California) with a 5 IrBiz transducer (focal zone = 3.5 cm) in sector mode to detect the scattering capability of the sample solution_ The compression was adjusted to obtain the greatest dynamic range possible, i.e. 60 d8. The time gain compensation control of the ultrasound system to was adjusted until the image sector being imaged ie judged visually to be optimal.
The imaging sequence was started by optimizing the instrument as described in 1.0 L of water at 37°C at transmit power. A 1.0 ml sample was then injected into the Water. Thereafter, every 2 minutes the transmit power was adjusted upwardB to 10, 20, 30, ~0, 50, 60, 70, 80, 90 and 99ic. The entire sequence of images was recorded on videotape (attached to the ultrasound system) for storage and analysis.
To prepare quantitative results of this experiment, videodensitometry analysis was performed.
Selected video frames stored on the videotape were digitized using an Apple Macintosh zh~computer equipped with a Data Translation QuickCapture~frame grabber board.
These frames were analyzed using CineProbe~ version 2.0 (Molecular Hioeyatems, San Diego, California) image processing software. A Region of Interest (ROI) within the beaker was selected and the mean pixel intensity (video brigritneee) within the region was determined.
Each frame was then analyzed as to its mean videodenaicy within the region of interest. The videodensity of a water blank is subtracted and the resultant videodensity is expressed as Video Hrightness yr Normalized Video Brightness when the initial value is set to 100 for comparison.
*Trade-mark WO 94!7,.8939 216 4 410 PCT/US9~110596s An ALHUNEX~ (MoleCUlar_Biasyatema, Ban Diego, California) (micrebubbles surrounded by a protein shell prepared as described in U.S. Patent Noa. 4,572,203;
4,718,433; 4,744,958; 4,844,882 and 4,957,656) control was also prepared and analyzed as described by injecting a 1.0 mL sample of ALHUNEXm (Molecular Hioeystems, San Diego, California) into 1.0 liter of 37°C water_ The results of this experiment are depicted in Figure lA and 1H. Due to the unchanging number of l0 microbubbles present in the ALBUNEX~ (Molecular Hiosystems, San. Diego, California) sample, there would be expected to be a linear relationship between transmit power and video brightness. This linear relationship is depicted in Pigure lA. In.comparison, using the emulsion of Example 1, there would be the expectation of a bilinear or step Lunction between video brightness and transmit power which would be due to some threshold energy of cavitation for micrvbubblea to be formed upon exposure to ultrasonic energy Such a relationship was observed, and these results are depicted in Figure IH.
The following components were added together and homogenized in the POLYTROtHm (Hrinkman, Westbury, New York) at 0°C for 3 minutes at 10,000 rpm while slowly adding 10 ml ultrapure water:
Trialein 0.6 g Glycerol 1.57 g Lecithin 0.6 g Pertluoropentane 1.5 g These components were further homogenized for an additional 2 minutes at 30,000 rpm to produce a milky white emulei.an. This emulsion was filtered successively thxough a 5 P. and 1.2 ~ filter. The particle size was determined in a Nicomp 770*(Particle Sizing Systems, *Trade-mark WO 94/28939 216 4 410 pCT/LTS94/05965 Santa Barbara, California) to be 95% less than 3.8 ~,. It was stable (no appreciable phase separation or particle size increase) for several days at 4°C. When imaged as described in Example 2, this emulsion demonstrated microbubble formation above 40% transmit power as observed in the ultrasonic image.
The following components were added together and homogenized in the POLYTRON~ (Brinkman, Westbury, New York) at 0°C for 3 minutes at 10,000 while slowly adding ml water:
Triolein 1.0 g Glycerol 1.0 g 15 a-Tocopherol 0.02 g PLURONIC~ F-68 0.2 g Gas-forming Chemical 1.5 g of one of the following:
Emulsion A: FCC13 (Fluorotrichloromethane) 20 Emulsion H: Br2F2C (Dibromodifluoromethane) Emulsion C: TMS (Tetramethylsilane) Emulsion D: 2-Methyl butane (Isopentane) The above emulsions were filtered through a 1.2 ~, filter and the particle sizes were determined as described in Example 4 to be:
A 95% less than 2.97 H 95% less than 4.02 C 95% less than 2.18 D 95% less than 2.99 ~C
The following components were added together and homogenized in the POLYTRON~ (Brinkman, Westbury, New York) at 0°C for 5 minutes at 10,000 rpm while slowly adding 20 ml water:
WO 94/28939 216 4 410 pCT/US94/05965 Triolein 1.0 g Glycerol 3.0 g a-Tocopherol 0.02 g Lecithin 1.0 g Perfluoropentane 1.0 g The emulsions were further homogenized for 3 minutes at 20,000 rpm and filtered successively through a 5 ~, and 1.2 ~, filter. The ultrasonic imaging characteristics of the emulsion were studied as described in Example 2 and exhibited microbubble formation above 40% transmit power as observed in the ultrasonic image.
To further study the effects of ultrasonic energy on the production of microbubbles, the emulsion of Example 5 (perfluoropentane) was imaged in two separate experiments either continually or in 30 second intervals.
For each experiment, a 1.0 ml sample of the emulsion was added to 1.0 liter of water at 37°C. In the first experiment, ultrasonic imaging as described in Example 2 was carried out at 99% transmit power continuously for 30 minutes. In the second experiment, the ultrasonic imaging was carried out for 30 second durations once every 5 minutes (intermittent imaging). Image brightness was quantified as described in Example 2 and the results are depicted in Figure 2. These results demonstrate that with continuous ultrasonic energy, due to the constant production of microbubbles and depletion of the bubble-forming capability of the emulsion, image brightness was significantly diminished at the end of 30 minutes. In comparison, with intermittent imaging which exposed the emulsions to only one-tenth the energy as compared to constant imaging (30 seconds every 5 minutes), the microbubble-forming capability of the emulsion persisted WO 94/28~'" 2 ~ 6 4 410 PCT/US94/05965 and a substantial amount of microbubbles continued to be produced even after 30 minutes.
An alternative emulsion formulation comprises a viscosifier, a stabilizer which is amphipathic and a gas-forming chemical formed by mixing together the following components in a final volume of 50 mL water:
Viscosifier: Stabilizer:
Emulsion A PLURONIC° F-68 Sucrose (8.6 g) (0.5 g) Emulsion B Sodium dodecyl- Sucrose (8.6 g) sulfate (1.44 g) Emulsion C PLURONIC° F-68 Lactose (9.0 g) (0.5 g) Emulsion D Sodium dodecyl- Lactose (9.0 g) sulfate (1.44 g) The solutions from above were filtered through a 0.2 ~, filter. A 10 mL aliquot of each of the above were mixed with 0.168 mL of perfluoropentane in the POLYTRON° (Brinkman, Westbury, New York) at 0°C for 1 to 3 minutes at 10,000 to 20,000 rpm and then for an additional 5 minutes at 20,000 rpm. Each of these four emulsions demonstrated microbubble formation as observed in the ultrasonic image above 40% transmit power when studied as described in Example 2.
To study the effects on these emulsions of continuous versus intermittent exposure to ultrasonic energy, a 1.0 mL sample of Emulsion C was placed in 1.0 liter of degassed water at 37°C. This solution was ultrasonically imaged either continuously or in intervals as described in Example 6. The results are depicted in Figure 3.
SYNTHESIS OF NONAFLUORO-t-BUTYL METHANE C4F9CH3 Starting materials (methyl iodide and cesium fluoride) were obtained from Aldrich Chemical Company and perfluoroisobutylene gas was obtained from Flura Corporation. Nuclear magnetic resonance spectra were obtained using a 200 MHz instrument tuned for determination of proton (1H) or fluorine (19F) resonances.
In a flask equipped with a gas inlet, mechanical stirrer and a dry ice condenser was placed a suspension of dry cesium fluoride (42.5 g, 0.279 mol) in diglyme (200 mL). Perfluoroisobutylene gas (55.5 g, 0.278 mol) was bubbled in. The gas reacted rapidly with cesium fluoride and a yellow solution resulted. The mixture was stirred for 30 minutes and then methyl iodide (38.5 g, 0.271 mol) was added dropwise. The reaction was slightly exothermic and the cesium iodide separated out.
The mixture was stirred for 3 hours and was allowed to stand overnight. A cold solution (2M, sodium chloride, 500 mL) was added to the mixture with cooling (5°C) for minutes. Sodium iodide and most of the diglyme solvent dissolved in the aqueous phase which was then decanted off from the solid giving a crude yield of 45 g 25 ( 40%). Distillation of the compound sublimed at head temperature 35-39°C and bath temperature not exceeding 50-55°C. The product was collected in a receiver cooled to -30°C with dry ice and ethanol. The proton 1H NMR
spectrum of its CDC13 solution showed a single resonance 30 relative to TMS; 1.65 (s, 3H, CH3) ppm (see Figure 4) and the 19F spectrum, in the same solvent, showed also one single resonance at -69.99 (s, 9F) ppm relative to CDC13 (see Figure 5).
NONAFLUORO-t-BUTYL METHANE C4F9CH3 is shown according to either of the following chemical formulas:
F
I
F-C - F
CFs F F
I I
F-C C C -F
FsC - C - CFs I I
F ~ F
CHs H-C.-H
I
H
The following components were mixed together and homogenized in the POLYTRON~ (Hrinkman, Westbury, New York) at 0°C for 3 minutes at 10,000 rpm while slowly adding 10 mL ultrapure water.
Triolein 1.01 g Glycerol 1.05 g cx-Tocopherol 0.02 g PLURONIC~ F-68 0.099 g C4F9CH3 0.780 g The resultant emulsion was filtered through a 5 ~. filter. The particle size was determined as described in Example 4 to be less than 4.30 microns.
The ultrasonic imaging characteristics of the 2'S emulsion were studied as described in Example 2. The formation of gas bubbles was observed even at low transmit power (<25%) settings which became brighter as the transrnit power was slowly increased to 99%.
Also for comparison a control experiment without C4F9CH3 was conducted by mixing the following components:
Triolein 1.01 g Glycerol 1.05 g a-Tocopherol 0.021 g PLURONIC° F-68 0.204 g I . ..._. . __ v VYO 94IZ8939 216 4 41 Q ~CT~US9di05965 The emulsion was prepared as described above.
In contrast to the pxevioua ultrasound imaging experiment, micropubble formation was not observed even at 99~ transmit power.
F~BM~E .10 The Following components were added together and homogenized in the P4LYTRON~ (Brinlanan, Westbury, New York) at 0°C for 2 minutes at 10,000 rpm while slowly adding 10 ml water:
Triolein 1_0 g Glycerol I.0 g a-Tocvpherol 0.03 g PLURONIC~ F-68 0_1 g 1$ Isvpentane 0.15 g n-Pentane 0_85 g The emulsion was further homogenized for 6 minutes at 30,000 rpm and filtered through a 1.2 filter. The ultrasonic imaging characteristics of the emulsion were studied ae described in Example 6 and a higher level v~ video brightness was observed with intermittent imaging than with continuous imaging.
EMULSION-CONTAININC3 ALBUMIN MICRaPARTZCLE
The emulsion of the present invention can be encapsulated into a delivery vehicle comprising a multi-chamber albumin matrix as follows:
A primary emulsion is prepared by first dissolving 2.0 g human aenim albumin in 20.0 ml buffer (0.45 N Na2C03, pH 9.8) and then adding I.0 g perfluoropentane. This mixture ie emulsified in an osteriaer*at high speed for 10 rninutee.
*Trade-mark tV0 94/x.8939 216 4 4 i 0 ~r/US94/DSg65 A double emulsion is then prepared by adding 100 ml Chloroform:Cyclohexane (1:4 v/v) with L0~ (v/v) sorbitan trioleate with continued mixing for 10 minutes.
The albumin is croeslinked by adding, while continuing to mix, an additional 100 m3 Chlorofozm:
Cyclohexane (1:4 v/v) containing 2.5 g terephthaloyl chloride and continuing to mix for an additional 30 minutes. The reaction is quenched with X00 mL of cyclohexane containing Sg polysorbate and 10~
(v/v) ethanolamine. The micrvcapsules are washed 3 times with cyclohexane:ethanol (i:i v/v), followed by 2 wa$hea in S~ polyavrbate-95~ ethanol, 2 washes in 95~ ethanol and a washes in water. The microparticles are then resuapended in normal saline and comprise multi-chambered vesicles containing an inner emulsiLied matrix of perfluoropentane.
Although the invention has been described primarily in connection with special and preferred embodiments, it will be u~derstvod that it is capable of modiLication without departing from the scope of the invention. The following claims are intended to cover all variations, uses or adaptations of the invention, following, in general, the principles thereof and including such departures from the present disclosure as come within known or customary practice in the field to which the invention pertains, or as are obvious to persons skilled in the art.
B
Claims (16)
1. An emulsion for use as an ultrasonic imaging agent comprising at least one water-insoluble gas-forming chemical and at least one stabilizer, said emulsion being capable of forming microbubbles of gas upon application of ultrasonic energy.
2. The emulsion of claim 1 wherein said stabilizer is a hydrophobic compound.
3. The emulsion of claim 2 wherein said emulsion includes a surface active agent.
4. The emulsion of claim 1 wherein said stabilizer is amphipathic.
5. The emulsion of claim 4 wherein said stabilizer is wherein the average value of n=75 and the average value of p=30 such that the average molecular weight of said stabilizer is 8350 daltons.
6. The emulsion of claim 1 wherein said emulsion includes a viscosifier.
7. The emulsion of claim 1 wherein said emulsion includes antioxidants.
8. The emulsion of claim 1 wherein said emulsion includes a component that imparts tissue specificity to said emulsion.
9. The emulsion of claim 1 wherein said emulsion includes a component that imparts organ specificity to said emulsion.
10. An ultrasound imaging agent comprising the emulsion of claim 1 and a delivery vehicle.
11. The ultrasound imaging agent of claim 10 wherein said delivery vehicle is selected from the group consisting of:
a natural polymer matrix, a synthetic polymer matrix and a liposome.
a natural polymer matrix, a synthetic polymer matrix and a liposome.
12. The ultrasound imaging agent of claim 11 wherein said natural polymer matrix is an albumin matrix.
13. The emulsion of claim 1 wherein said water-insoluble gas-forming chemical is nonafluoro-t-butylmethane.
14. The emulsion of claim 1 wherein said water-insoluble gas-forming chemical is perfluoropentane and said stabilizer is lecithin.
15. A method to enhance the contrast of tissue and organs in an ultrasonic image comprising. (a) injecting the emulsion or imaging agent of claims 1-14 into a patient; (b) applying a sufficient amount of ultrasonic energy to volatilize said chemicals to release microbubbles; and (c) detecting an ultrasonic image.
16. The use of an emulsion or imaging agent according to any of claims 1 to 14 to enhance the contrast of tissues and organs in an ultrasonic image, which forms microbubbles of gas on application of sufficient ultrasonic energy.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/072,535 | 1993-06-04 | ||
US08/072,535 US5716597A (en) | 1993-06-04 | 1993-06-04 | Emulsions as contrast agents and method of use |
PCT/US1994/005965 WO1994028939A1 (en) | 1993-06-04 | 1994-05-26 | Emulsions as contrast agents and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2164410C true CA2164410C (en) | 2000-02-22 |
Family
ID=22108224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002164410A Expired - Fee Related CA2164410C (en) | 1993-06-04 | 1994-05-26 | Emulsions as contrast agents and method of use |
Country Status (10)
Country | Link |
---|---|
US (3) | US5716597A (en) |
EP (2) | EP0852145A3 (en) |
JP (2) | JP3016592B2 (en) |
AT (1) | ATE169828T1 (en) |
CA (1) | CA2164410C (en) |
DE (1) | DE69412610T2 (en) |
DK (1) | DK0701451T3 (en) |
ES (1) | ES2120053T3 (en) |
GR (1) | GR3027727T3 (en) |
WO (1) | WO1994028939A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220080243A1 (en) * | 2020-09-11 | 2022-03-17 | Honeywell International Inc. | Azeotrope or azeotrope-like compositions of trifluoroiodomethane (cf3i) and water |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773024A (en) | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5656211A (en) | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5705187A (en) | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US20020150539A1 (en) * | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
USRE39146E1 (en) | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US20010024638A1 (en) * | 1992-11-02 | 2001-09-27 | Michel Schneider | Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof |
US6989141B2 (en) * | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
IN172208B (en) | 1990-04-02 | 1993-05-01 | Sint Sa | |
US7083778B2 (en) * | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6613306B1 (en) | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US20030194376A1 (en) * | 1990-05-18 | 2003-10-16 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US6723303B1 (en) | 1991-09-17 | 2004-04-20 | Amersham Health, As | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
MX9205298A (en) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | GASEOUS ULTRASOUND CONTRASTING MEDIA AND METHOD FOR SELECTING GASES TO BE USED AS ULTRASOUND CONTRASTING MEDIA |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
US6875420B1 (en) | 1991-09-17 | 2005-04-05 | Amersham Health As | Method of ultrasound imaging |
GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) * | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Phase shift colloids as ultrasound contrast agents |
CA2154590C (en) * | 1993-01-25 | 2001-06-12 | Steven C. Quay | Phase shift colloids as ultrasound contrast agents |
US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
DE69434119T3 (en) * | 1993-07-30 | 2011-05-05 | Imcor Pharmaceutical Co., San Diego | STABILIZED MICROGAS BLOWER COMPOSITIONS FOR ECHOGRAPHY |
US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
PT682530E (en) * | 1993-12-15 | 2003-06-30 | Bracco Research Sa | UTEIS GAS MIXTURES AS CONTRAST MEANS FOR ULTRASSONS |
US5736121A (en) | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US5897851A (en) * | 1995-06-07 | 1999-04-27 | Sonus Pharmaceuticals, Inc. | Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging |
US6139819A (en) * | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6548046B1 (en) * | 1995-06-08 | 2003-04-15 | Barnes-Jewish Hospital | Site specific binding system, imaging compositions and methods |
US6821506B2 (en) | 1995-06-08 | 2004-11-23 | Barnes-Jewish Hospital | Site specific binding system, imaging compositions and methods |
JPH0924269A (en) * | 1995-07-10 | 1997-01-28 | M Technic Kk | Manufacture of micro-capsule using phosphorous lipid |
US5840276A (en) * | 1996-01-11 | 1998-11-24 | Apfel Enterprises, Inc. | Activatable infusable dispersions containing drops of a superheated liquid for methods of therapy and diagnosis |
EP0935415B1 (en) | 1996-05-01 | 2006-11-22 | Imarx Pharmaceutical Corp. | In vitro methods for delivering nucleic acids into a cell |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
ATE366588T1 (en) | 1996-09-11 | 2007-08-15 | Imarx Pharmaceutical Corp | METHOD FOR DIAGNOSTIC IMAGING OF THE KIDNEY REGION USING A CONTRAST AGENT AND A VASODILATOR |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
TR199901544T2 (en) * | 1996-10-21 | 1999-09-21 | Nycomed Imaging As | Advances in or related to contrast agents. |
GB9622711D0 (en) | 1996-10-31 | 1997-01-08 | British Tech Group | Instrument having enhanced ultrasound visibility |
US6537246B1 (en) * | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
US6416740B1 (en) * | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
AU7702798A (en) * | 1997-05-30 | 1998-12-30 | Alliance Pharmaceutical Corporation | Methods and apparatus for monitoring and quantifying the movement of fluid |
US20030032879A1 (en) * | 1997-07-07 | 2003-02-13 | Steven Quay | Microbubble formation using ultrasound |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
GB9726773D0 (en) * | 1997-12-18 | 1998-02-18 | Nycomed Imaging As | Improvements in or relating to ultrasonagraphy |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
US6171245B1 (en) * | 1998-03-12 | 2001-01-09 | Siemens Medical Systems, Inc. | Method of imaging scatterers based on acoustically stimulated changes of their acoustic properties |
US20040131547A1 (en) * | 1998-04-22 | 2004-07-08 | Balin Balinov | Contrast agents |
GB9808599D0 (en) * | 1998-04-22 | 1998-06-24 | Nycomed Imaging As | Improvements in or realting to contrast agents |
US7686763B2 (en) * | 1998-09-18 | 2010-03-30 | University Of Washington | Use of contrast agents to increase the effectiveness of high intensity focused ultrasound therapy |
US6444192B1 (en) | 1999-02-05 | 2002-09-03 | The Regents Of The University Of California | Diagnostic imaging of lymph structures |
FR2795633A1 (en) * | 1999-06-30 | 2001-01-05 | Oreal | USE IN A MAKEUP REMOVER OR CLEANSING COSMETIC COMPOSITION OF AT LEAST ONE VOLATILE FLUORINE COMPOUND |
US7510536B2 (en) * | 1999-09-17 | 2009-03-31 | University Of Washington | Ultrasound guided high intensity focused ultrasound treatment of nerves |
US7520856B2 (en) * | 1999-09-17 | 2009-04-21 | University Of Washington | Image guided high intensity focused ultrasound device for therapy in obstetrics and gynecology |
US7220401B2 (en) * | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
AU2619301A (en) | 1999-10-25 | 2001-06-06 | Therus Corporation | Use of focused ultrasound for vascular sealing |
US6626855B1 (en) | 1999-11-26 | 2003-09-30 | Therus Corpoation | Controlled high efficiency lesion formation using high intensity ultrasound |
US7179449B2 (en) | 2001-01-30 | 2007-02-20 | Barnes-Jewish Hospital | Enhanced ultrasound detection with temperature-dependent contrast agents |
DE10119522A1 (en) * | 2001-04-20 | 2002-12-05 | Innovacell Biotechnologie Gmbh | Preparation and application of a suspension composition with an ultrasound contrast medium |
US6979296B2 (en) * | 2002-04-03 | 2005-12-27 | Sbm Biologics, Inc. | Methods for ultrasonic imaging and treating diseased tissues |
US7357937B2 (en) * | 2002-09-24 | 2008-04-15 | Therox, Inc. | Perfluorocarbon emulsions with non-fluorinated surfactants |
EP1569595B1 (en) * | 2002-12-10 | 2008-05-21 | Gambro Lundia AB | A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
US20110040171A1 (en) * | 2003-12-16 | 2011-02-17 | University Of Washington | Image guided high intensity focused ultrasound treatment of nerves |
US20060033072A1 (en) * | 2004-04-16 | 2006-02-16 | Honeywell International Inc. | Stabilized trifluoroiodomethane compositions |
US8012457B2 (en) * | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
US9066679B2 (en) | 2004-08-31 | 2015-06-30 | University Of Washington | Ultrasonic technique for assessing wall vibrations in stenosed blood vessels |
US8611189B2 (en) * | 2004-09-16 | 2013-12-17 | University of Washington Center for Commercialization | Acoustic coupler using an independent water pillow with circulation for cooling a transducer |
WO2006043359A1 (en) * | 2004-10-22 | 2006-04-27 | Hitachi Medical Corporation | Ultrasonic contrast medium |
CN100574811C (en) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | A kind of particle analog assistant for high-intensity focusing ultrasonic therapy and application thereof |
CN100574809C (en) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | A kind of high-strength focusing ultrasonic therapy fluorocarbon emulsion analog assistant and application thereof |
JP4630127B2 (en) * | 2005-05-17 | 2011-02-09 | 株式会社日立製作所 | Ultrasound diagnostic treatment device |
WO2007021958A2 (en) * | 2005-08-12 | 2007-02-22 | University Of Washington | Method and apparatus for preparing organs and tissues for laparoscopic surgery |
US8414494B2 (en) * | 2005-09-16 | 2013-04-09 | University Of Washington | Thin-profile therapeutic ultrasound applicators |
US8016757B2 (en) * | 2005-09-30 | 2011-09-13 | University Of Washington | Non-invasive temperature estimation technique for HIFU therapy monitoring using backscattered ultrasound |
US8167805B2 (en) | 2005-10-20 | 2012-05-01 | Kona Medical, Inc. | Systems and methods for ultrasound applicator station keeping |
WO2007127958A2 (en) * | 2006-04-27 | 2007-11-08 | Barnes-Jewish Hospital | Detection and imaging of target tissue |
JP5162923B2 (en) * | 2007-02-27 | 2013-03-13 | 株式会社日立製作所 | Ultrasonic imaging device |
JP5124185B2 (en) * | 2007-07-02 | 2013-01-23 | 株式会社日立製作所 | Method and apparatus for preparing a diagnostic or therapeutic drug |
WO2009155353A1 (en) * | 2008-06-17 | 2009-12-23 | The Regents Of The University Of California | Process and system for reducing sizes of emulsion droplets and emulsions having reduced droplet sizes |
US20100160781A1 (en) * | 2008-12-09 | 2010-06-24 | University Of Washington | Doppler and image guided device for negative feedback phased array hifu treatment of vascularized lesions |
US8517962B2 (en) | 2009-10-12 | 2013-08-27 | Kona Medical, Inc. | Energetic modulation of nerves |
US20160059044A1 (en) | 2009-10-12 | 2016-03-03 | Kona Medical, Inc. | Energy delivery to intraparenchymal regions of the kidney to treat hypertension |
US8986231B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
US8295912B2 (en) | 2009-10-12 | 2012-10-23 | Kona Medical, Inc. | Method and system to inhibit a function of a nerve traveling with an artery |
US8469904B2 (en) | 2009-10-12 | 2013-06-25 | Kona Medical, Inc. | Energetic modulation of nerves |
US9174065B2 (en) | 2009-10-12 | 2015-11-03 | Kona Medical, Inc. | Energetic modulation of nerves |
US20110092880A1 (en) | 2009-10-12 | 2011-04-21 | Michael Gertner | Energetic modulation of nerves |
US9119951B2 (en) | 2009-10-12 | 2015-09-01 | Kona Medical, Inc. | Energetic modulation of nerves |
US20110118600A1 (en) | 2009-11-16 | 2011-05-19 | Michael Gertner | External Autonomic Modulation |
US8986211B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
US9427410B2 (en) | 2010-10-08 | 2016-08-30 | The University Of North Carolina At Chapel Hill | Formulation of acoustically activatable particles having low vaporization energy and methods for using same |
US20140046181A1 (en) * | 2011-01-05 | 2014-02-13 | The Regents Of The University Of California | Acoustically responsive particles with decreased cavitation threshold |
WO2013028639A1 (en) * | 2011-08-19 | 2013-02-28 | The Trustees Of Princeton University | C-halogen bond formation |
US9982290B2 (en) | 2012-10-04 | 2018-05-29 | The University Of North Carolina At Chapel Hill | Methods and systems for using encapsulated microbubbles to process biological samples |
US10925579B2 (en) | 2014-11-05 | 2021-02-23 | Otsuka Medical Devices Co., Ltd. | Systems and methods for real-time tracking of a target tissue using imaging before and during therapy delivery |
CN109983111B (en) * | 2016-11-24 | 2021-01-19 | 松下知识产权经营株式会社 | Micro-bubble generation accelerator, micro-bubble-containing liquid, and method and apparatus for producing micro-bubble-containing liquid |
AU2018297329A1 (en) * | 2017-07-07 | 2020-01-23 | Drexel University | Voltage-activated therapeutic, diagnostic, and/or theranostic constructs |
JP2021519275A (en) * | 2018-03-23 | 2021-08-10 | ユニヴァーシティ オブ ワシントン | Immunosuppressive materials and related methods |
JP2022064317A (en) * | 2020-10-13 | 2022-04-25 | トスレック株式会社 | Ufb aqueous solution generation device, ufb aqueous solution generation method and aqueous solution |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3778381A (en) * | 1972-04-24 | 1973-12-11 | Allied Chem | Fluorocarbon microemulsions |
US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
DE3141641A1 (en) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION |
US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
US4572203A (en) * | 1983-01-27 | 1986-02-25 | Feinstein Steven B | Contact agents for ultrasonic imaging |
US4622219A (en) * | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
US4725442A (en) * | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
US5219538A (en) * | 1987-03-13 | 1993-06-15 | Micro-Pak, Inc. | Gas and oxygen carrying lipid vesicles |
US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
JP2907911B2 (en) * | 1988-02-05 | 1999-06-21 | シエーリング アクチエンゲゼルシヤフト | Ultrasound contrast agent, method for producing the same, and diagnostic or therapeutic preparation comprising the ultrasound contrast agent |
US4996041A (en) * | 1988-08-19 | 1991-02-26 | Toshiyuki Arai | Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system |
US4993415A (en) * | 1988-08-19 | 1991-02-19 | Alliance Pharmaceutical Corp. | Magnetic resonance imaging with perfluorocarbon hydrides |
DE3828905A1 (en) * | 1988-08-23 | 1990-03-15 | Schering Ag | MEDIALLY COMPOSED OF CAVITATE OR CLATHRATE MAKING HOST / GUEST COMPLEX AS A CONTRAST |
US4957656A (en) * | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
US5234680A (en) * | 1989-07-31 | 1993-08-10 | Johns Hopkins Univ. | Perfluoro-t-butyl-containing compounds for use in fluorine-19 NMR and/or MRI |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5123414A (en) * | 1989-12-22 | 1992-06-23 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
IN172208B (en) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5137928A (en) * | 1990-04-26 | 1992-08-11 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
AU635449B2 (en) * | 1990-10-05 | 1993-03-18 | Bracco International B.V. | Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography |
DE4100470A1 (en) * | 1991-01-09 | 1992-07-16 | Byk Gulden Lomberg Chem Fab | Echo contrast agent |
GB9106673D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
US5147631A (en) * | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
JP3231768B2 (en) * | 1991-09-17 | 2001-11-26 | ソーナス ファーマシューティカルス,インコーポレイテッド | Gaseous ultrasonic contrast agent and method for selecting gas to be used as ultrasonic contrast agent |
WO1994006477A1 (en) * | 1992-09-16 | 1994-03-31 | Holmes, Michael, John | Improvements in or relating to contrast agents |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
CA2154590C (en) * | 1993-01-25 | 2001-06-12 | Steven C. Quay | Phase shift colloids as ultrasound contrast agents |
GB9305349D0 (en) * | 1993-03-16 | 1993-05-05 | Nycomed Imaging As | Improvements in or relating to contrast agents |
-
1993
- 1993-06-04 US US08/072,535 patent/US5716597A/en not_active Expired - Fee Related
-
1994
- 1994-05-26 CA CA002164410A patent/CA2164410C/en not_active Expired - Fee Related
- 1994-05-26 EP EP98101252A patent/EP0852145A3/en not_active Withdrawn
- 1994-05-26 WO PCT/US1994/005965 patent/WO1994028939A1/en not_active Application Discontinuation
- 1994-05-26 ES ES94919260T patent/ES2120053T3/en not_active Expired - Lifetime
- 1994-05-26 DK DK94919260T patent/DK0701451T3/en active
- 1994-05-26 AT AT94919260T patent/ATE169828T1/en not_active IP Right Cessation
- 1994-05-26 EP EP94919260A patent/EP0701451B1/en not_active Revoked
- 1994-05-26 JP JP7501860A patent/JP3016592B2/en not_active Expired - Lifetime
- 1994-05-26 DE DE69412610T patent/DE69412610T2/en not_active Expired - Fee Related
-
1995
- 1995-05-12 US US08/439,693 patent/US5536489A/en not_active Expired - Fee Related
-
1997
- 1997-12-23 US US08/996,736 patent/US6030603A/en not_active Expired - Fee Related
-
1998
- 1998-08-26 GR GR980401907T patent/GR3027727T3/en unknown
- 1998-10-14 JP JP10292638A patent/JPH11193247A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220080243A1 (en) * | 2020-09-11 | 2022-03-17 | Honeywell International Inc. | Azeotrope or azeotrope-like compositions of trifluoroiodomethane (cf3i) and water |
Also Published As
Publication number | Publication date |
---|---|
US5536489A (en) | 1996-07-16 |
WO1994028939A1 (en) | 1994-12-22 |
EP0701451B1 (en) | 1998-08-19 |
EP0852145A2 (en) | 1998-07-08 |
DE69412610D1 (en) | 1998-09-24 |
DK0701451T3 (en) | 1998-12-14 |
US5716597A (en) | 1998-02-10 |
JP3016592B2 (en) | 2000-03-06 |
JPH08509984A (en) | 1996-10-22 |
DE69412610T2 (en) | 1999-01-14 |
EP0701451A1 (en) | 1996-03-20 |
GR3027727T3 (en) | 1998-11-30 |
US6030603A (en) | 2000-02-29 |
EP0852145A3 (en) | 2000-07-05 |
ES2120053T3 (en) | 1998-10-16 |
JPH11193247A (en) | 1999-07-21 |
ATE169828T1 (en) | 1998-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2164410C (en) | Emulsions as contrast agents and method of use | |
US6136293A (en) | Stable microbubbles suspensions containing saturated lamellar phospholipids | |
US5562893A (en) | Gas-filled microspheres with fluorine-containing shells | |
EP0907380B1 (en) | Pressure resistant protein microspheres as ultrasonic imaging agents | |
JPH11508871A (en) | Novel composition of lipids and stabilizing substances | |
JP2001514615A (en) | Delivery method for bioactive agents | |
EP0689461B1 (en) | Improvements in or relating to contrast agents | |
US20010019710A1 (en) | Contrast agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |